Skip to main content

Table 1 Clinical characteristics of laparoscopic radical prostatectomy cases treated with or without neoadjuvant hormonal therapy groups * p< 0.05

From: Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy

Variables LRP* alone LRP with NHT**
No. of patients 270 72
Mean age ± SD 66.3 ± 6.1 67.7 ± 5.4
Mean serum PSA ± SD, ng/mL 8.64 ± 5.2 9.81 ± 4.1
Biopsy Gleason grade, n(%)
 ≤ 3 + 3 121 (44.8) 30 (41.7)
 3 + 4, 4 + 3 85 (31.5) 25 (34.7)
 ≥ 4 + 4 64 (23.7) 17 (23.6)
Clinical stage, n(%)
 cT1c 100 (37.0) 27 (37.5)
 cT2 170 (63.0) 45 (62.5)
D’Amico risk classification, n(%)
 low 76 (28.1) 14 (19.4)
 intermediate 74 (27.4) 24 (33.3)
 high 120 (44.4) 34 (47.2)
Pathological stage, n(%)
 pT2 193 (71.5) 62 (86.1)
 pT3 77 (28.5) *10 (13.9)
Median operative time, min 260 (121–572) 276 (151–454)
Median blood loss, ml 600 (50–4500) 600 (90–3928)
Intraoperative complication
 Rectum injury, n(%) 4 (1.48) 2 (2.78)
 Blood transfusion, n(%) 4 (1.48) 2 (2.78)
 Open surgery conversion, n(%) 10 (3.70) 3 (4.17)
Positive surgical margin, n(%) 114 (42.2) *20 (27.8)
Biochemical recurrence, n(%) 48 (17.8) 14 (19.4)
  1. Patient characteristics and outcomes in laparoscopic prostatectomy (LRP) only and LRP with neoadjuvant hormone therapy (NHT) *p < 0.05.
  2. LRP*: laparoscopic radical prostatectomy NHT**: neoadjuvant hormonal therapy.